| Literature DB >> 32266221 |
Fengxuan Han1,2, Jiayuan Wang1,2, Luguang Ding1,2, Yuanbin Hu3, Wenquan Li4, Zhangqin Yuan1,2, Qianping Guo1,2, Caihong Zhu1,2, Li Yu1,2, Huan Wang1,2, Zhongliang Zhao1,2, Luanluan Jia1,2, Jiaying Li1,2, Yingkang Yu1,2, Weidong Zhang1,2, Genglei Chu1, Song Chen1,2, Bin Li1,2,5.
Abstract
Exploring innovative solutions to improve the healthcare of the aging and diseased population continues to be a global challenge. Among a number of strategies toward this goal, tissue engineering and regenerative medicine (TERM) has gradually evolved into a promising approach to meet future needs of patients. TERM has recently received increasing attention in Asia, as evidenced by the markedly increased number of researchers, publications, clinical trials, and translational products. This review aims to give a brief overview of TERM development in Asia over the last decade by highlighting some of the important advances in this field and featuring major achievements of representative research groups. The development of novel biomaterials and enabling technologies, identification of new cell sources, and applications of TERM in various tissues are briefly introduced. Finally, the achievement of TERM in Asia, including important publications, representative discoveries, clinical trials, and examples of commercial products will be introduced. Discussion on current limitations and future directions in this hot topic will also be provided.Entities:
Keywords: Asia; biomaterials; biomechanics; cell sources; regenerative medicine; tissue engineering
Year: 2020 PMID: 32266221 PMCID: PMC7105900 DOI: 10.3389/fbioe.2020.00083
Source DB: PubMed Journal: Front Bioeng Biotechnol ISSN: 2296-4185
FIGURE 1(A) An interwoven aligned conductive nanofiber yarn/hydrogel hybrid scaffolds for mimicking the native cardiac tissue structure (reproduced with permission from Wu et al., 2017). (B) A thin, long, and finely handleable cell fiber fabricated by using a microfluidic device (reproduced with permission from Onoe et al., 2013).
Examples of MSC used in tissue engineering and regenerative medicine in Asia.
| Cells | Disease | Mode of stem cell application | References |
| Bone marrow stem cell (BMSC) | Bone injury | 1. BMSC and endothelial progenitor cell mixture for large segment of bone defect | |
| Cartilage injury | 1. Reconstruction of human-ear-shaped cartilage by co-culturing chondrocytes | ||
| Spinal cord injury | 1. BMSC-derived extracellular vesicles to repair spinal cord injury | ||
| Lung injury | 1. Mice BMSCs were injected into mice via the tail vein to treat acute lung | ||
| Liver cirrhosis | Autologous BMSCs transplantation in human | ||
| Severe Asherman syndrome | GFP-labeled BMSCs was injected systemically through the tail vein in rat | ||
| Intrauterine adhesion | BMSC-loaded elastic poly(glycerol sebacate) scaffold | ||
| Hearing loss | BMSC transplantation recovery functional restoration of mouse cochleae | ||
| Peripheral nerve injury | BMSC-derived acellular matrix-coated chitosan/silk scaffold | ||
| Type 2 diabetes | Autologous BMSCs transplantation in human | ||
| Adipose mesenchymal stromal cell (ADSC) | Osteoarthritis | ADSCs with hyaluronic acid were intra-articularly injected into the knee | |
| Cartilage injury | 1. ADSC/hyaluronic acid (HA)-modified thermoresponsive | ||
| Bone injury | MiR-135-modified ADSC | ||
| Intervertebral disc injury | ADSC-derived tissue-engineered construct | ||
| Stricture after extended esophageal endoscopic submucosal dissection | ADSC-sheet transplantation | ||
| Urethral defect | Polylactid acid fibrous membrane seeded with ADSC | ||
| Atrophied muscle | Autologous ADSCs transplantation | ||
| Type 2 diabetes | Autologous ADSCs transplantation |
Summary of direct reprogramming by lineage-specific transcription factors.
| Original cells | Reprogramming factors | Induced cells |
| Oct4/Sox2/Klf4/c-Myc (mouse and human) | Pluripotent stem cell | |
| 1. Brn2/Ascl1/Myt1l (BAM) (mouse) | Excitatory neuron | |
| 2. BAM/NeuroD1 (human) | ||
| BAM/Lhx3/Hb9/lsl1/Ngn2 (mouse) | Motor neuron | |
| Ascl1/Nurr1/Lmx1a (mouse and human) | Dopaminergic neuron | |
| Fibroblast | Sox2 (mouse and human) | Neural stem cell |
| 1. Hnf4a/Foxa1 (mouse) | Hepatocyte | |
| 2. Hnf1a/Hnf4a/Hnf6/Atf5/Prox1/Cebpa (human) | ||
| Erg/Gata2/Lmo2/Runx1c/Scl (mouse) | Hematopoietic progenitor cell | |
| Foxo1/Er71/Klf2/Tal/Lmo2 (mouse) | Endothelial cell | |
| Gata4/Mef2c/Tbx5 (mouse) | Cardiomyocyte | |
| MyoD | Skeletal myocyte | |
| Exocrine cell | 1. Neurogenin3/Pdx1/Mafa (mouse) | Pancreatic β-cell |
| 2. Epidermal growth factor/ciliary neurotrophic factor (mouse) | ||
| Myeloid cell | Run1t1/Jlf/Lmo2/Prdm5/Pbx1/Zfp37 | Hematopoietic stem cell |
FIGURE 2Future cardiac regenerative therapy by cell transplantation-based approach using iPS cell-derived cardiomyocytes (Upper) and direct cardiac reprogramming approach (Lower) (reproduced with permission from Sadahiro et al., 2015).
FIGURE 3The number of publications in different Asian countries (A), and different fields in China (B), Japan (C), and South Korea (D) from 2009 to 2019.
Examples of clinical trials on MSC cell therapy.
| NCT | Disease | MSC source | Objectives | Country | Status |
| NCT01302015 | Buerger’s disease | Autologous ADSCs | Treat patient with Buerger’s disease | South Korea | Completed Estimated study Completion Date: June 2019 |
| NCT01309061 | Romberg’s disease | Human ADSCs | Treat patient with progressive hemifacial atrophy | South Korea | Completed Estimated study Completion Date: June 2019 |
| NCT00979758 | Myocardial infarction | Bone marrow mononuclear cells | Improve the outcome of patients with impaired left ventricle function after myocardial infarction | China | Completed Estimated study Completion Date: January 2018 |
| NCT02948023 | Corneal injuries | Treat different superficial corneal pathologies in human | India | Recruiting Estimated study Completion Date: March 2018 | |
| NCT02260713 | Acute spinal cord injury | Autologous bone marrow cells | Treat acute complete spinal cord injury | India | Completed Estimated study Completion Date: March 2018 |
| NCT02669199 | Large area skin wound injury | Allogeneic umbilical cord derived MSCs | Treat large area skin lesions of the subjects | China | Recruiting Estimated study Completion Date: February 2016 |
| NCT00981006 | Ischemic cardiomyopathy | Autologous human cardiac-derived stem cell | Treat severe refractory heart failure patients with chronic ischemic cardiomyopathy concordance with reduced left ventricular dysfunction | Japan | Completed Estimated study Completion Date: April 2015 |
| NCT02338271 | Intervertebral disc degeneration | Autologous ADSCs | Treat chronic low back pain patients with lumbar intervertebral disc degeneration | South Korea | Completed Estimated study Completion Date: January 2015 |
Examples of 3D bioprinting companies and products in Asia.
| Company | Project/products | Founding year | Country | Website |
| Next 21 | Custom-made artificial bone implants | 2000 | Japan | |
| Osteopore International | Osteoplug; Osteomesh | 2003 | Singapore | |
| Cyfuse Biomedical | Bone, cartilage, blood vessel, neural tissue, liver | 2010 | Japan | |
| Regenovo Biotechnology | Bone, blood vessel, cartilage | 2013 | China | |
| SUNP BIOTECH | Custom-made products, bioink, bioprinter | 2014 | China | |
| Rokit | Skin, bioink, bioprinter | South Korea | ||
| Pandorum Technologies | Liver, cornea | 2011 | India |